Free Trial
OTCMKTS:NSPX

Inspyr Therapeutics (NSPX) Stock Price, News & Analysis

About Inspyr Therapeutics Stock (OTCMKTS:NSPX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
29.64 million shs
Average Volume
13.19 million shs
Market Capitalization
$1.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

Receive NSPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inspyr Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NSPX Stock News Headlines

EWTX Edgewise Therapeutics, Inc.
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).
See More Headlines

NSPX Stock Analysis - Frequently Asked Questions

Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) posted its earnings results on Monday, August, 14th. The company reported ($26.25) earnings per share for the quarter.

Inspyr Therapeutics shares reverse split on the morning of Tuesday, October 12th 2021. The 1-75 reverse split was announced on Tuesday, October 12th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 12th 2021. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of NSPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inspyr Therapeutics investors own include Stem (STEM), Hon Hai Precision Industry Co., Ltd. Sponsored GDR (HNHPF), iBio (IBIO), Knight-Swift Transportation (KNX), Blink Charging (BLNK), BIO-key International (BKYI) and BIOLASE (BIOL).

Company Calendar

Last Earnings
8/14/2017
Today
6/23/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:NSPX
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.30 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.07) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$1.47 million
Optionable
Not Optionable
Beta
-17.33
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (OTCMKTS:NSPX) was last updated on 6/23/2025 by MarketBeat.com Staff
From Our Partners